Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Skin" returned 7 results:

Phase II Trial of Nab-Paclitaxel as First Line cytotoxic Chemotherapy in Patients with Unresectable Cutaneous Squamous Cell Carcinoma
Principal Investigator(s): Philip Friedlander

A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
Principal Investigator(s): Yvonne Saenger

A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer
Principal Investigator(s): Philip Friedlander

The Effect of BRAF Inhibition with Vemurafenib on the Innate and Adaptive Immune Systems in Patients with Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation
Principal Investigator(s): Philip Friedlander

A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
Principal Investigator(s): Dr. Nina Bhardwaj

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
Principal Investigator(s): Yvonne Saenger

A Phase II Study of MK-3475 in Patents with Advanced Merkel Cell Carcinoma
Principal Investigator(s): Dr. Philip Friedlander